SEC Form 4 · accession 0001209191-15-002245
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Jan 2, 2015
Accepted (ET)
Jan 6, 2015 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2015 | M | 2,291 | $73.51 | A | 86,791 | D | |
| Common Stock | Jan 2, 2015 | S | 100 | $119.03 | D | 86,691 | D | |
| Common StockF2,F3 | Jan 2, 2015 | S | 1,200 | $122.35 | D | 85,491 | D | |
| Common StockF3,F4 | Jan 2, 2015 | S | 991 | $123.12 | D | 84,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $73.51 | Jan 2, 2015 | M | 2,291 | D | — | Jan 1, 2024 | Common Stock | 2,291 | 45,835 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $122.35 (range $121.75 to $122.74).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $123.12 (range $122.78 to $123.33).
- F5The option vests in 16 quarterly installments from 01/02/2014.